# Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

> **NCT00315861** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 15 (estimated)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer
- Lung Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00315861
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-05
- **Final completion:** 2009-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2009-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00315861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00315861, "Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00315861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*